vinblastine / Generic mfg. - LARVOL DELTA

Nivo40-AVD for Advanced Classic Hodgkin Lymphoma (clinicaltrials.gov) - P2 | N=54 | Recruiting | Sponsor: National Medical Research Radiological Centre of the Ministry of Health of Russia

New P2 trial • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Balancing the Burden: Comparing Treatment Burden of IV vs. Oral Therapy in Pediatric Brain Tumors (ASPHO 2025) - " Intravenous (IV) therapy (carboplatin/vincristine and cisplatin/cyclophosphamide/ etoposide/vincristine) was associated with more total adverse events (n = 39) compared to oral therapy (larotrectinib, selumetinib, trametinib/dabrafenib, n = 20) and combination IV and oral therapy (vinblastine and selumetinib, n = 15). Physicians need to recognize the differences in treatment burdens between IV and oral therapies for pediatric brain tumor patients. Our findings revealed that IV therapy was associated with a higher number of adverse events, especially gastrointestinal events, and increased healthcare utilization, including more frequent clinic visits, compared to oral therapies. Further research is needed to evaluate the efficacy of oral treatment compared with IV therapy."

Clinical • Brain Cancer • Gastrointestinal Disorder • Glioma • Oncology • Pediatrics • Solid Tumor

THE EFFICACY AND SAFETY OF LUVOMETINIB (FCN-159) IN PEDIATRIC PATIENTS WITH REFRACTORY/RELAPSED LANGERHANS CELL HISTIOCYTOSIS: A MULTI-CENTER, OPEN-LABEL, SINGLE-ARM PHASE II STUDY (EHA 2025) - P2 | "Current first-line treatment recommended by Histiocyte Society for children with multifocal disease is vinblastine and prednisone. For patients with risk-organ involvement, additional 6-mercaptopurine is also used as maintenance therapy...While cobimetinib has been approved for the treatment of adult patients, it has not yet been approved for pediatric patients... The preliminary study results showed that luvometinib was highly efficacious for pediatric patients with refractory/relapsed LCH. In addition, luvometinib was well tolerated, without TRAEs-induced discontinuation reported. Trial Information: NCT05997602, CTR20232238."

Clinical • P2 data • Anemia • Dermatitis • Dermatology • Genetic Disorders • Hematological Disorders • Immunology • Infectious Disease • Langerhans Cell Histiocytosis • Neurofibromatosis • Pediatrics • Rare Diseases • Solid Tumor • ARAF • BRAF • CD1a

SELINEXOR IN COMBINATION WITH R-EPOCH FOR PATIENTS WITH PREVIOUSLY UNTREATED HIV-ASSOCIATED DLBCL: A SINGLE-CENTER, PROSPECTIVE, SINGLE-ARM TRIAL (EHA 2025) - P4 | "The study was designed to evaluate safety and efficacy of selinexor (60mg Days 1, 8, 15) combined with R-EPOCH(rituximab 375 mg/m2 d1, etoposide 50 mg/m2 d1-d4, doxorubicin 10mg/m2 d1-d4, vinblastine 0.4mg/m2 d1-d4, prednisone 60mg/m2 d1-d5 and cyclophosphamide 750mg/m2 d5) every 3 weeks in HIV-DLBCL. XR-EPOCH demonstrated a favorable efficacy and manageable safety in HIV-DLBCL patients."

Clinical • Combination therapy • IO biomarker • Anemia • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Neutropenia • Oncology • Thrombocytopenia • ARID2 • CD4 • FAT1 • GNA13 • PAX5 • PCLO • TP53 • XPO1

Selecting optimal therapy for Langerhans cell histiocytosis: current state and future directions. (PubMed, Expert Opin Pharmacother) - No abstract available

Journal • Langerhans Cell Histiocytosis

Dual MEK and BRAF Inhibition in Neonate With Refractory Multi-System Langerhans Cell Histiocytosis (ASPHO 2025) - "Objectives: To report treatment response to combination dabrafenib and trametinib and highlight ocular complications in a very young infant with refractory MS, RO+BRAFV600+ LCH, refractory to first line treatment with vinblastine and prednisone (as per LCH III), Vemurafenib (monotherapy), and cladribine (single course)...Although there was radiographic improvement, patient was switched to vemurafenib that month because of persistent liver dysfunction and profound edema, requiring continual repletion with albumin and diuresis with furosemide... We present the youngest patient with refractory multi-system LCH treated on dual MEK and BRAF inhibitor therapy published in the literature."

Gastrointestinal Disorder • Hematological Malignancies • Hepatology • Langerhans Cell Histiocytosis • Liver Failure • Ocular Inflammation • Oncology • Ophthalmology • Solid Tumor • Uveitis • CD1a

EVALUATION OF FIRST-LINE TREATMENT WITH ABVD REGIMEN IN PATIENTS WITH ADVANCED STAGE HODGKIN LYMPHOMA (STAGE III-IV) (EHA 2025) - "The ABVD (Doxorubicin, Bleomycin, Vinblastine, Dacarbazine) regimen remains the standard first-line therapy, though novel targeted agents are emerging as alternatives. Despite comparable response rates to international data, the observed CR rate was lower than global reports (typically 70-80%), likely influenced by limited access to radiotherapy and emerging targeted therapies. This study underscores the need for improved access to radiotherapy and the evaluation of novel agents, such as Brentuximab Vedotin and PD-1 inhibitors, in the Mexican HL population. Further prospective studies are warranted to refine treatment strategies and improve patient outcomes."

Clinical • Metastases • Epstein-Barr Virus Infections • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

IMPACT OF OMISSION OF BLEOMYCIN ON LONG TERM SURVIVAL IN ADVANCED STAGE HODGKIN LYMPHOMA IMPACT OF OMISSION OF BLEOMYCIN ON LONG TERM SURVIVAL IN ADVANCED STAGE HODGKIN LYMPHOMA (EHA 2025) - "Background: The omission of bleomycin is a widely adopted practice in patients with advanced-stage classic Hodgkin lymphoma (cHL) who achieve a complete metabolic response (CMR) after the second cycle of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD). Our study supports that omitting bleomycin from the ABVD regimen in patients with advanced-stage HL who achieve a complete response after two cycles does not significantly impact progression-free or overall survival, consistent with the findings of the RATHL trial."

Metastases • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

REFRACTORY AND/OR RELAPSED HODGKIN'S LYMPHOMA: A MONOCENTRIC EXPERIENCE OF THE HEMATOLOGY DEPARTMENT OF MONASTIR. (EHA 2025) - "The first line chemotherapy received was ABVD (Adriamycin, Bleomycin, Vinblastine and Dacarbazine) in 8 patients (27.6%) and BEACOPP (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine and Prednisolone) in 21 patients (72.4%).The salvage treatment for our study population included DHAOx (Dexamethasone, High dose Cytarabine and Oxaliplatin): 5 (17.3%), Bendamustine-Brentuximab: 5 (17.3%), BEACOPP: 12 (41.4%), ABVD: 4 (13.7%) and other regimens: 3 (10.3%). In conclusion, our population is characterized by a young age with a slight male predominance, and a predominantly advanced disease, but the salvage treatment was effective, and we obtained remission rates and overall survival rates comparable to the results described in the literature."

Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

TREATMENT OF PATIENTS WITH HISTIOCYTOSIS: RETROSPECTIVE MONOCENTRIC EXPERIENCE (EHA 2025) - "Three patients were treated with indomethacin (2 unifocal bone and 1 single system bone), obtaining PR in 2 cases and CR in 1 case, while 1 patient was treated with interferon α (single system bone). Seven patients were treated with vinblastine and steroids (2 single system CNS and lymph nodes, 5 multisystem), all obtained PR; 5 patients were treated with cladribine subcutaneously (1 histiocytic sarcoma and 4 multisystem), resulting in PR in 3 cases and progression in 1 case, while in 1 case treatment is still ongoing... Decision process for treatment of histiocytosis is complex and response to therapy is still unsatisfactory among patients with multisystemic involvement and histiocytic sarcoma. Routine molecular characterization would be desirable to acquire new data that could lead to the development of drug targets. In the meantime, our data show that sarcomas are often refractory to polychemotherapy, while unifocal and single-system disease usually reach a good..."

Retrospective data • Langerhans Cell Histiocytosis • Oncology • Rare Diseases • Sarcoma • Solid Tumor

A CLINICAL CHALLENGE: PEMBROLIZUMAB-INDUCED CARDIOTOXICITY IN A TEENAGER WITH HODGKIN LYMPHOMA - CASE REPORT AND LITERATURE REVIEW (EHA 2025) - "The International Prognostic Score (IPS) was 5, indicating a poor prognosis, leading to the initiation of first-line chemotherapy with BEACOPDac (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, vincristine,dacarbazine and Prednisone)...Due to treatment toxicity, a switch to the ABVD (Adriamycin, Bleomycin, Vinblastine, and Dacarbazine) regimen was made, but no favorable tumor response was achieved. Given the disease progression, salvage chemotherapy with the ICE regimen (Ifosfamide, Carboplatin, Etoposide) was initiated... The emergence of immunotherapy and its gradual expansion in hematology and oncology will necessitate heightened vigilance to promptly detect and appropriately manage potential cardiac toxicities.It is crucial for clinicians to recognize such acute and life-threatening toxicities to initiate corticosteroid therapy without delay."

Case report • Clinical • Review • Cardiovascular • Classical Hodgkin Lymphoma • Congestive Heart Failure • Follicular Lymphoma • Heart Failure • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Oncology • Pulmonary Embolism • Respiratory Diseases • Septic Shock • Ventricular Tachycardia

EFFICACY AND SAFETY OF NIVOLUMAB IN COMBINATION WITH AVD IN PATIENTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA: A PROSPECTIVE SINGLE-CENTER CLINICAL TRIAL (EHA 2025) - "Patients received nivolumab dose of 3 mg/kg, days 1 and 15 of a 28-day cycle in combination chemotherapy AVD (doxorubicin 25 mg/m2, vinblastine 6 mg/m2, dacarbazine 375 mg/m2) was then administered for 6 cycles followed by interim PET-CT (PET2). The obtained results of the study demonstrate high efficacy and acceptable toxicity of the N-AVD protocol in patients with newly diagnosed cHL, especially in extremely severe patients with generalized HL with a high prognostic index and poor somatic status. However, a longer observation period is required"

Clinical • Combination therapy • Acute Myelogenous Leukemia • Classical Hodgkin Lymphoma • Endocrine Disorders • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infertility • Leukemia • Lymphoma • Myelodysplastic Syndrome • Neutropenia • Oncology • Sexual Disorders

BV-AVD 1ST LINE TREATMENT RETROSPECTIVE ANALYSIS, KUWAIT CANCER CENTER EXPERIENCE. (EHA 2025) - "Background: Background: Brentuximab vedotin (BV) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) has demonstrated its efficacy as front-line treatment for advanced stage Hodgkin lymphoma (HL) in clinical trials Aims: The aim of this study is to explore the real-world effectiveness of this treatment regimen in the Middle Eastern population at the Kuwait Cancer Center (KCC). The regimen shows effectiveness for advanced-stage Hodgkin lymphoma in the Middle Eastern population at the KCC,supporting BV-AVD as a viable front-line therapy, though further studies are needed to confirm findings."

Retrospective data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

THE APPLICATION OF MINIGENE TRANSCRIPTION ANALYSIS IN THE DIAGNOSIS AND TREATMENT OF INFANTILE MYOFIBROMATOSIS (IM) WITH HEMOPHILIA A (EHA 2025) - "In IM with visceral involvement, the most common treatment is chemical regimens such as intravenous application of vinblastine and methotrexate. There are also reports that cases associate with mutations in PDGFRB are sensitive to TKI such as imatinib, etc. Aims: Assist in confirming the diagnosis of IM in the child and provide reasonable recommendations for clinical treatment... We report a case of infantile myofibromatosis (IM) in a patient with concomitant hemophilia A. Whole-genome sequencing revealed novel intronic mutations in the F8 and PDGFRB genes. Through Minigene transcription analysis, we validated the impact of the PDGFRB gene intronic mutation on PDGFRB gene function, further confirming the diagnosis of IM. We also suggest that if the patient's condition progresses, TKI therapy could be considered."

Hematological Disorders • Hemophilia • Hemophilia A • Mood Disorders • Oncology • Rare Diseases • Respiratory Diseases • Solid Tumor • F8 • PDGFRB

A SURVIVAL UPDATE ON A PHASE II TRIAL USING CONVENTIONAL CHEMOTHERAPY PLUS NIVOLUMAB IN ADVANCED STAGE HODGKIN DISEASE (HD) (EHA 2025) - "Background: Patients with advanced stages III,IV HD can be cured in 75-80% of cases using the conventional ABVD (doxorubicin+ bleomycin+ vinblastine + Dacarbazine), however; the minority of patients still challenging in term of progression during treatment or resistance to chemotherapy. The addition of Brentuximab vedotin can have a synergistic effect to the backbone chemotherapy AVD. Addition of Nivolumab from the very beginning can modulate the cancer microenvironment through activation of CD8 and triggering the immunologic function. This combination seems to be promising in the category of patients presenting with an advanced stage high risk score HD patients"

Metastases • P2 data • Hematological Disorders • Hodgkin Lymphoma • Neutropenia • Oncology • Pain • CD8

TREATMENT EFFICACY FOR ADVANCED-STAGE CLASSIC HODGKIN LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS (EHA 2025) - "BV-based regimens only included BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) and BV-AVD (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine). Chemotherapy regimens only included ABVD and eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses) *4-6 cycles regimen... This systematic review and meta-analysis of frontline studies in advanced stage cHL underscores the high efficacy of BV-based PET-regimens in 3- and 5-year OS and PFS rates."

Metastases • Retrospective data • Review • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

ERDHEIM-CHESTER DISEASE IN A 28-YEAR-OLD FEMALE MANAGED WITH VINBLASTINE-PREDNISONE PROTOCOL, A CASE REPORT (EHA 2025) - "In conclusion, Erdheim-Chester Disease is rare, characterized by infiltration of foamy histiocytes affecting middle-aged adults with male predominance. In this case, ECD is presented in a 28-year old female. This case is the second reported case of ECD presenting in an age 20-30."

Case report • Clinical • Fibrosis • Immunology • Inflammation • Langerhans Cell Histiocytosis • Rare Diseases • ALK • CD1a • CD68 • NRAS

A MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON OF BRECADD VS PET-GUIDED ABVD AND EBEACOPP IN ADVANCED HODGKIN LYMPHOMA (EHA 2025) - "Background: Brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD) is a recommended front-line regimen for the management of advanced Hodgkin Lymphoma (aHL) in recent treatment guidelines. Other widely used regimens are positron emission tomography (PET)-guided doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone (eBEACOPP)... Among adult aHL patients, BrECADD was associated with significantly improved PFS and OS compared to PET-guided ABVD per RATHL and SWOG S0816 protocols. A similar trend in OS was observed against BEACOPP in older adults. These results further support the use of BrECADD over PET-guided ABVD and BEACOPP-based treatment in both younger and older adult aHL patients."

Metastases • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

FIVE-YEAR EXPERIENCE WITH PD-1 INHIBITOR COMBINATION REGIMENS IN REFRACTORY CLASSIC HODGKIN LYMPHOMA AFTER FAILURE OF IMMUNE CHECKPOINT INHIBITOR MONOTHERAPY (EHA 2025) - "The regimens included nivo at a dose of 3 mg/kg or 40 mg every 2 weeks in combination with only one of the following agents: bendamustine (benda) 90 mg/m² on days 1 and 2 of a 28-day cycle, vinblastine (vin) 10 mg every 2 weeks, brentuximab vedotin (BV) 1.8 mg/kg every 3 weeks, or gemcitabine (gem) 800-1000 mg every 2 weeks. Combination therapy based on PD-1 inhibitors is an effective strategy in patients with r/r cHL after nivo monotherapy failure. This option may be a good strategy both for preparing patients for alloHCT and for providing therapy with palliative intent in refractory patients."

Checkpoint inhibition • Monotherapy • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Improved efficacy of concurrent anti-PD1 antibody plus AVD versus ABVD in patients with newly diagnosed early unfavorable and advanced stage classic Hodgkin lymphoma: a retrospective matched cohort study. (PubMed, Cancer Immunol Immunother) - "In this real-world study, concurrent anti-PD1 antibody with AVD showed significantly prolonged modified PFS and improved CR rate after cycle 2 versus ABVD regimen, supporting the use of novel agents in frontline therapy."

Clinical • Journal • Retrospective data • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

VICTORY: Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas (clinicaltrials.gov) - P1 | N=57 | Recruiting | Sponsor: Daniel Morgenstern | Trial primary completion date: Mar 2026 ➔ Mar 2027

Trial primary completion date • Brain Cancer • Glioma • Oncology • Pediatrics • Solid Tumor • BRAF

Predictors in Optic Pathway Gliomas in Neurofibromatosis Type 1: A Single Center Study. (PubMed, Cancers (Basel)) - "The first line of oncological treatment included vincristine + carboplatin or monotherapy with vinblastine. The use of subsequent lines of oncological treatment was necessary in 46.7% patients. The following conclusions, suggest modification of the approach in the management of patients with NF1-OPG, summarize the presented study: (1) perform the first MRI after the age of 1 year, (2) reduce the frequency of follow-up scans in the first year of observation in patients with isolated involvement of intraocular and/or intraorbital segments of the optic nerve, (3) refrain from administering contrast during control MRI examinations of the orbits after OPG diagnosis; (4) in patients with co-occurring psychomotor delay or treated with antiepileptic drugs, do not make decisions about oncological therapy when visual acuity deterioration is observed, without progression in optical coherence tomography (OCT), visual evoked potentials (VEP), and MRI."

Journal • Brain Cancer • CNS Disorders • Epilepsy • Genetic Disorders • Glioma • Neurofibromatosis • Oncology • Ophthalmology • Solid Tumor • Strabismus • NF1

Tailoring Treatment of Hodgkin Lymphoma in Patients With Sickle Cell Disease: A Case Series (ASPHO 2025) - "He was treated with doxorubicin, vinblastine, dacarbazine, and Nivolumab as per protocol S1826 to avoid corticosteroids and minimize the risk of vaso-occlusive crisis...He was treated with brentuximab vedotin, doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide as per AHOD1331 with modifications including steroid taper to prevent rebound pain crises and intermittent filgrastim rather than pegylated formation to avoid the risk of rebound leukocytosis and VOC... There are important limitations that must be considered when treating a patient with both SCD and cancer. For both of our patients, therapy was adapted based on the patient's individual complications from SCD and modified to avoid therapies that could further exacerbate those complications. Special attention was paid to the use of steroids, granulocyte colony-stimulating factor, and radiation therapy along with frequent monitoring of hemoglobin S percentage."

Clinical • Cardiovascular • Classical Hodgkin Lymphoma • CNS Disorders • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Pain • Pediatrics • Sickle Cell Disease

Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors (clinicaltrials.gov) - P1/2 | N=63 | Active, not recruiting | Sponsor: Centre Oscar Lambret | Trial completion date: Jan 2028 ➔ Jan 2027

IO biomarker • Trial completion date • Brain Cancer • Ependymoma • Pediatrics • Solid Tumor

Sustained Complete Response to Lorlatinib Monotherapy in a Child With Multiply Relapsed ALK+ ALCL (ASPHO 2025) - " An 8-year-old male diagnosed with ALK+ ALCL received initial treatment per ANHL12P1 with brentuximab with complete response...His critical illness improved rapidly with initiation of dexamethasone, vinblastine, and crizotinib...The anti-PD-1 ICI, nivolumab, was initiated, but the patient experienced diffuse systemic recurrence within eight weeks... ALK-directed therapy is a critical and effective component of treatment for relapsed pediatric ALK+ ALCL, but questions remain regarding optimal agents, duration of therapy, and efficacy in the multiply relapsed setting. Here, we report the first pediatric patient with ALK+ ALCL successfully treated with lorlatinib, an ALK-inhibitor being studied in adults with ALK+ ALCL. This patient experienced an isolated CNS, second relapse post-HSCT shortly after stopping crizotinib maintenance therapy."

Clinical • Monotherapy • Bone Marrow Transplantation • Dyslipidemia • Hematological Disorders • Hypertriglyceridemia • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • Respiratory Diseases • ALK